Industry News
Technique for identifying microorganisms
Scientists at the US Department of Energy's Brookhaven National Laboratory have developed a high-throughput technique for identifying the many species of microorganisms living in an unknown 'microbial community'.
[ + ]Application to characterise structure of DNA molecules
An application to enable more precise measurement of the location of a fluorescent label in a DNA layer has been developed by a team of researchers from Boston University in the US.
[ + ]Positive phase I data for Novogen's bowel disease drug
A recently completed phase I clinical trial of biopharmaceutical company Novogen's (ASX:NRT) anti-inflammatory compound NV-52 has shown rapid absorption indicating its potential as an oral therapy, according to the company. [ + ]
Zenyth in-licenses antibody patents from Ludwig
Melbourne's Zenyth Therapeutics (ASX:ZTL), formerly Amrad, has in-licensed patents from the Ludwig Institute for Cancer Research for antibodies that target a key part of the inflammatory process. [ + ]
'Frustrating' delays for Chemeq's regulatory approval
Regulatory approval for Chemeq's (ASX:CMQ) polymeric antimicrobial CHEMEQ has been delayed in some jurisdictions, pushing expected registrations out in some cases to 2007. [ + ]
Vaccine researcher critical of CSL, govt approaches to bird flu
A leading researcher has raised the ire of CSL (ASX:CSL), saying the Melbourne company is "making the wrong vaccine for bird flu." [ + ]
SCS, Chemicon launch ES cell products
Stem Cell Sciences (AIM:STEM, SCS) and Californian-based Chemicon are set to launch a new product line of culture media for mouse embryonic stem cells. [ + ]
Australians to tap into crop testing in Europe
A company has been established in Adelaide to develop scientific techniques for genetic crop testing in Europe.
[ + ]Depression vulnerability gene confirmed
An Australian replication study has strengthened evidence that individuals who inherit a common variant of the serotonin transporter gene 5-HTT are more vulnerable to major depression after adverse events in their lives. [ + ]
CathRx files for cardiac catheters CE Mark
CathRx (ASX:CXD) has taken the first step in the CE Mark approval process for its cardiac diagnostic catheters. [ + ]
Clinuvel begins controlled-release implant trial
Melbourne's Clinuvel Pharmaceuticals (ASX:CUV), formerly Epitan, has begun a trial in Adelaide of its lead drug CUV1647 in a controlled-release pellet form. [ + ]
BioDiem revenue up, loss under $100,000
Milestone payments from partner Nobilon led to Melbourne's BioDiem (ASX:BDM) posting strong results for the half year ending December 31, 2005 with revenue up 88 per cent to $2.9 million and a loss of only $96,000 compared with the previous corresponding half. [ + ]
Peacock appointed Australia's chief scientist
Pioneering CSIRO plant molecular geneticist Dr Jim Peacock, has been appointed Australia's chief scientist, in the wake of the resignation of Dr Robin Batterham after six years in the job. [ + ]
Past five years show life sciences industry growth
The Australian life sciences industry has grown significantly in the past five years and shows signs of a positive future, according to the 15th edition of PricewaterhouseCoopers' quarterly BioForum report. [ + ]
Bavarian Nordic looking for strategic partner, says company chairman
Denmark's Bavarian Nordic is actively seeking to be part of the consolidation process now underway in the international vaccine industry, and would not turn down a takeover offer if the price were right, company chairman Asgar Aamund said on Tuesday. [ + ]
